Cover Image
市場調查報告書

骨髓移植手術:開發中產品分析

Bone Marrow Transplantation - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 251563
出版日期 內容資訊 英文 76 Pages
訂單完成後即時交付
價格
Back to Top
骨髓移植手術:開發中產品分析 Bone Marrow Transplantation - Pipeline Review, H1 2016
出版日期: 2016年03月30日 內容資訊: 英文 76 Pages
簡介

骨髓移植手術是以健康的骨髓幹細胞來移植取代受損或被破壞的骨髓之傳統療法。骨髓移植會引起胸部疼痛、發冷、血壓低、發熱、臉紅、口內異味、頭痛、蕁麻疹、噁心、疼痛及呼吸急促等。主要的治療方法為使用免疫疾病抑製藥。

本報告提供骨髓移植手術的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

骨髓移植手術概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

骨髓移植手術:企業開發中的治療藥

骨髓移植手術:大學/機關研究中的治療藥

骨髓移植手術:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

骨髓移植手術:企業開發中的產品

骨髓移植手術:大學/機關研究中的產品

骨髓移植手術的治療藥的開發企業

  • Anchor Therapeutics, Inc.
  • Boryung Pharmaceutical Co., Ltd.
  • Cleveland BioLabs, Inc.
  • Compugen Ltd.
  • Mesoblast Limited
  • Pluristem Therapeutics Inc.
  • Taiga Biotechnologies, Inc.
  • Targazyme, Inc.

骨髓移植手術:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

骨髓移植手術:最近的開發平台趨勢

骨髓移植手術:暫停中的計劃

骨髓移植手術:開發中止的產品

骨髓移植手術:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7761IDB

Summary

Global Markets Direct's, 'Bone Marrow Transplantation - Pipeline Review, H1 2016', provides an overview of the Bone Marrow Transplantation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bone Marrow Transplantation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bone Marrow Transplantation and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Bone Marrow Transplantation
  • The report reviews pipeline therapeutics for Bone Marrow Transplantation by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Bone Marrow Transplantation therapeutics and enlists all their major and minor projects
  • The report assesses Bone Marrow Transplantation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Bone Marrow Transplantation

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Bone Marrow Transplantation
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bone Marrow Transplantation pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Bone Marrow Transplantation Overview
  • Therapeutics Development
    • Pipeline Products for Bone Marrow Transplantation - Overview
    • Pipeline Products for Bone Marrow Transplantation - Comparative Analysis
  • Bone Marrow Transplantation - Therapeutics under Development by Companies
  • Bone Marrow Transplantation - Therapeutics under Investigation by Universities/Institutes
  • Bone Marrow Transplantation - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Bone Marrow Transplantation - Products under Development by Companies
  • Bone Marrow Transplantation - Products under Investigation by Universities/Institutes
  • Bone Marrow Transplantation - Companies Involved in Therapeutics Development
    • Anchor Therapeutics, Inc.
    • Boryung Pharmaceutical Co., Ltd.
    • Cleveland BioLabs, Inc.
    • Compugen Ltd.
    • Mesoblast Limited
    • Pluristem Therapeutics Inc.
    • Taiga Biotechnologies, Inc.
    • Targazyme, Inc.
  • Bone Marrow Transplantation - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (filgrastim + plerixafor) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ATI-2341 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BR-05001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CBLB-612 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy for Bone Marrow Transplantation - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CGEN-15001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MPC-CBE - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PLXR-18 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Protein for Bone Marrow Transplantation - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Perforin for Bone Marrow Transplantation - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TZ-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Bone Marrow Transplantation - Recent Pipeline Updates
  • Bone Marrow Transplantation - Dormant Projects
  • Bone Marrow Transplantation - Discontinued Products
  • Bone Marrow Transplantation - Product Development Milestones
    • Featured News & Press Releases
      • Jan 12, 2016: Pluristem Receives U.S. FDA Clearance to Initiate Clinical Trial of PLX-R18 to Treat Insufficient Hematopoietic Recovery Following Bone Marrow Transplant
      • Nov 17, 2015: Pluristem to Present New Data on PLX-R18 at American Society of Hematology's Annual Meeting
      • May 06, 2015: Pluristem Granted European Patent for Use of Cells to Help Treat Damaged Bone Marrow
      • Mar 24, 2015: Pluristem Announces Key Strategic Objectives for Development of PLX-R18 in Hematopoietic Indications
      • Mar 03, 2015: Pluristem and Hadassah Medical Center Announce Significant Data Showing PLX-R18 Cells Improve Bone Marrow Transplantation
      • Dec 04, 2014: Pluristem and Hadassah Medical Center Will Collaborate to Study Potential of PLX-RAD Cells to Improve Bone Marrow and Umbilical Cord Blood Transplant Outcomes
      • Nov 13, 2014: Cell Source's Megadose Drug Combination Receives Regulatory Approval in Italy to Commence Human Clinical Trials
      • Oct 27, 2014: Case Western Reserve University to Study Pluristem's PLX-RAD Cells in Umbilical Cord Blood Transplants for the Treatment of Blood Cancers and Genetic Diseases
      • May 07, 2013: Pluristem Develops PLX-RAD Cells For Use In Hematology
      • Sep 05, 2012: Pluristem Therapeutics Announces Successfully Treatment Of Third Critically Ill Patient With PLX Cells Under Compassionate Use
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Bone Marrow Transplantation, H1 2016
  • Number of Products under Development for Bone Marrow Transplantation - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Bone Marrow Transplantation - Pipeline by Anchor Therapeutics, Inc., H1 2016
  • Bone Marrow Transplantation - Pipeline by Boryung Pharmaceutical Co., Ltd., H1 2016
  • Bone Marrow Transplantation - Pipeline by Cleveland BioLabs, Inc., H1 2016
  • Bone Marrow Transplantation - Pipeline by Compugen Ltd., H1 2016
  • Bone Marrow Transplantation - Pipeline by Mesoblast Limited, H1 2016
  • Bone Marrow Transplantation - Pipeline by Pluristem Therapeutics Inc., H1 2016
  • Bone Marrow Transplantation - Pipeline by Taiga Biotechnologies, Inc., H1 2016
  • Bone Marrow Transplantation - Pipeline by Targazyme, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Bone Marrow Transplantation Therapeutics - Recent Pipeline Updates, H1 2016
  • Bone Marrow Transplantation - Dormant Projects, H1 2016
  • Bone Marrow Transplantation - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Bone Marrow Transplantation, H1 2016
  • Number of Products under Development for Bone Marrow Transplantation - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top